摘要
目的探讨盐酸美金刚治疗帕金森痴呆患者临床疗效。方法截选本院90例帕金森痴呆患者按照随机数字表法分为对照组与治疗组,每组各45例。两组患者均采用抗帕金森药物等常规治疗,对照组采用盐酸多奈哌齐片治疗;治疗组采用盐酸美金刚治疗。治疗12周,分别于治疗前、治疗12周后采用帕金森病评定量表(UPDRS)评价其病情控制情况,采用蒙特利尔认知评估量表(Mo CA)评价其认知功能改善情况;采用简易精神状态量表(MMSE)评价其认知功能缺损改善状态;采用日常生活能力(ADL)量表评价其日常生活能力情况。并于治疗前、后分别检测其血清重组人帕金森病蛋白7(PARK7)、C反应蛋白(CRP)及神经营养因子NT-3水平;统计两组不良反应。结果两组治疗后UPDRS评分明显低于治疗前,MMSE、ADL及Mo CA评分明显高于治疗前,治疗组治疗后UPDRS评分明显低于对照组,而MMSE、ADL及Mo CA评分明显高于对照组,P<0.05。两组患者治疗后血清PAPK7及CRP水平明显低于治疗前,而NT-3水平明显高于治疗前,治疗组治疗后PARK7及CRP水平明显低于对照组,NT-3水平明显高于对照组,P<0.05。治疗期间无明显不良反应发生。结论应用盐酸美金刚治疗帕金森痴呆可改善患者认知功能及日常生活能力,且具有较高的安全性。
Objective To investigate the clinical efficacy of memantine hydrochloride on cognitive function and ability of daily living in patients with Parkinson’s dementia.Methods 90 cases of patients with Parkinson’s dementia were selected and randomly divided into the control group（n=45）and the treatment group（n=45）.All of patients were treated with conventional treatment,the patients in control group received hydrochloride donepezil,while the patients in treatment group were treated by memantine hydrochloride.The duration of treatment was 12 weeks.The Parkinson’s Disease Rating Scale（UPDRS）,Montreal Cognitive Assessment（Mo CA）,daily living scale（ADL） and mini-mental state examination（MMSE）were used to evaluate two group of patients.The serum PAPK7,CRP and NT-3 level were measured before and after treatment.Results After treatment,the UPDRS scores,the serum PARK7 and CRP levels of patients in the treatment group were significantly lower than those in the control group,while the scores of MMSE,ADL,Mo CA and the serum CRP levels were significantly higher than those in the control group.Conclusion Application of memantine hydrochloride can significantly improve the cognitive function and activities of daily living of patients with Parkinson’s dementia.
出处
《国际精神病学杂志》
2017年第6期1064-1066,共3页
Journal Of International Psychiatry
关键词
帕金森痴呆
盐酸美金刚
盐酸多奈哌齐片
认知功能
日常生活能力
Parkinson’s dementia
Memantine hydrochloride
Donepezil hydrochloride tablets
Cognitive function
Daily living
